{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:13:49Z","timestamp":1768832029767,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s12185-024-03857-2","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T20:22:12Z","timestamp":1728591732000},"page":"694-704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Improved survival among elderly patients with aggressive adult T-cell leukemia\/lymphoma: Impact of mogamulizumab-containing chemotherapy"],"prefix":"10.1007","volume":"120","author":[{"given":"Miki","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6137-890X","authenticated-orcid":false,"given":"Takeharu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Horai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiro","family":"Itonaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"3857_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","volume":"50","author":"T Uchiyama","year":"1977","unstructured":"Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481\u201392.","journal-title":"Blood"},{"key":"3857_CR2","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","volume":"77","author":"BJ Poiesz","year":"1980","unstructured":"Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980;77:7415\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3857_CR3","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","volume":"79","author":"M Yoshida","year":"1982","unstructured":"Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A. 1982;79:2031\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3857_CR4","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1111\/cas.14658","volume":"111","author":"Y Imaizumi","year":"2020","unstructured":"Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, et al. Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: a nationwide hospital-based study. Cancer Sci. 2020;111:4567\u201380.","journal-title":"Cancer Sci"},{"key":"3857_CR5","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","volume":"25","author":"K Tsukasaki","year":"2007","unstructured":"Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan clinical oncology group study JCOG9801. J Clin Oncol. 2007;25:5458\u201364.","journal-title":"J Clin Oncol"},{"key":"3857_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s12185-014-1665-0","volume":"100","author":"J Makiyama","year":"2014","unstructured":"Makiyama J, Imaizumi Y, Tsushima H, Taniguchi H, Moriwaki Y, Sawayama Y, et al. Treatment outcome of elderly patients with aggressive adult T cell leukemia-lymphoma: Nagasaki University Hospital experience. Int J Hematol. 2014;100:464\u201372.","journal-title":"Int J Hematol"},{"key":"3857_CR7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837\u201342.","journal-title":"J Clin Oncol"},{"key":"3857_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/bjh.13338","volume":"169","author":"T Ishida","year":"2015","unstructured":"Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169:672\u201382.","journal-title":"Br J Haematol"},{"key":"3857_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428\u201337.","journal-title":"Br J Haematol"},{"key":"3857_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"3857_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"3857_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.7164\/antibiotics.32.1085","volume":"32","author":"D Dantchev","year":"1979","unstructured":"Dantchev D, Paintrand M, Hayat M, Bourut C, Math\u00e9 G. Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot (Tokyo). 1979;32:1085\u20136.","journal-title":"J Antibiot (Tokyo)"},{"key":"3857_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hon.815","volume":"25","author":"H Tsurumi","year":"2007","unstructured":"Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, et al. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70\u00a0years or older with diffuse large B-cell lymphoma. Hematol Oncol. 2007;25:107\u201314.","journal-title":"Hematol Oncol"},{"key":"3857_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1600-0609.2010.01411.x","volume":"84","author":"Y Takamatsu","year":"2010","unstructured":"Takamatsu Y, Suzumiya J, Utsunomiya A, Maeda K, Matsuoka H, Suzushima H, et al. THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia\/lymphoma: a multicenter phase II study. Eur J Haematol. 2010;84:391\u20137.","journal-title":"Eur J Haematol"},{"key":"3857_CR15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s12185-021-03150-6","volume":"114","author":"S Kida","year":"2021","unstructured":"Kida S, Fuji S, Morishima T, Nakata K, Miyashiro I, Ishikawa J. Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry. Int J Hematol. 2021;114:246\u201351.","journal-title":"Int J Hematol"},{"key":"3857_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3960\/jslrt.22026","volume":"62","author":"K Ohmachi","year":"2022","unstructured":"Ohmachi K, Ogura M, Kagami Y, Imai Y, Hirose T, Kinoshita T, et al. A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma. J Clin Exp Hematop. 2022;62:202\u20137.","journal-title":"J Clin Exp Hematop"},{"key":"3857_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","volume":"27","author":"K Tsukasaki","year":"2009","unstructured":"Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453\u20139.","journal-title":"J Clin Oncol"},{"key":"3857_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3857_CR19","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","volume":"30","author":"H Katsuya","year":"2012","unstructured":"Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma. J Clin Oncol. 2012;30:1635\u201340.","journal-title":"J Clin Oncol"},{"key":"3857_CR20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bjh.12962","volume":"166","author":"T Fukushima","year":"2014","unstructured":"Fukushima T, Nomura S, Shimoyama M, Shibata T, Imaizumi Y, Moriuchi Y, et al. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol. 2014;166:739\u201348.","journal-title":"Br J Haematol"},{"key":"3857_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/bjh.14634","volume":"181","author":"M Tokunaga","year":"2018","unstructured":"Tokunaga M, Yonekura K, Nakamura D, Haraguchi K, Tabuchi T, Fujino S, et al. Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma. Br J Haematol. 2018;181:539\u201342.","journal-title":"Br J Haematol"},{"key":"3857_CR22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/ejh.12863","volume":"98","author":"M Sekine","year":"2017","unstructured":"Sekine M, Kubuki Y, Kameda T, Takeuchi M, Toyama T, Kawano N, et al. Effects of mogamulizumab in adult T-cell leukemia\/lymphoma in clinical practice. Eur J Haematol. 2017;98:501\u20137.","journal-title":"Eur J Haematol"},{"key":"3857_CR23","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s12185-018-2509-0","volume":"108","author":"J Nakashima","year":"2018","unstructured":"Nakashima J, Imaizumi Y, Taniguchi H, Ando K, Iwanaga M, Itonaga H, et al. Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma. Int J Hematol. 2018;108:516\u201323.","journal-title":"Int J Hematol"},{"key":"3857_CR24","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","volume":"126","author":"H Katsuya","year":"2015","unstructured":"Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126:2570\u20137.","journal-title":"Blood"},{"key":"3857_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3390\/v14040791","volume":"14","author":"T Kato","year":"2022","unstructured":"Kato T, Imaizumi Y, Miyazaki Y. Nationwide hospital-based survey of adult T-cell leukemia\/lymphoma in Japan. Viruses. 2022;14:791.","journal-title":"Viruses"},{"key":"3857_CR26","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/bjh.18281","volume":"198","author":"T Shichijo","year":"2022","unstructured":"Shichijo T, Nosaka K, Tatetsu H, Higuchi Y, Endo S, Inoue Y, et al. Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma. Br J Haematol. 2022;198:983\u20137.","journal-title":"Br J Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03857-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03857-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03857-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T14:05:33Z","timestamp":1732543533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03857-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3857"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03857-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yasushi Miyazaki is an associate editor of International Journal of Hematology. Yasushi Miyazaki has received honoraria from Astellas Pharma, Chugai, Kyowa Kirin, Nippon Shinyaku, Novartis, Abbvie, Bristol-Myers Squibb, Sumitomo Pharma, SymBio, Daiichi Sankyo, and has received research funding from Chugai. Y. Imaizumi has received honoraria from Chugai, Sanofi, Daiichi Sankyo, SymBio, Meiji Seika Pharma, Astra\u00a0Zeneca, Bristol-Myers Squibb, Kyowa Kirin. All the remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}